Clinical trial · Interventional
Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
Investigating Absorbed Radiation Dose Delivered to Differentiated Thyroid Cancer Metastases Following Administration of Fixed Activity of Radioactive Iodine
NCT00749697CI-TRIAL-00001673unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Sites Lung Bone Nodal | Thyroid Gland Neoplasm | PROBABILISTIC | 0.70 |
| Thyroid Carcinoma | Thyroid Gland Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SPECT scan | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The primary outcome measure is to correlate the predicted dose from the tracer study with the actual absorbed dose measure on the therapeutic scan
Secondary outcomes (1)
- measure
- The secondary outcomes will be to assess the response at 6 months post therapy in each patient
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age above 18 * histological confirmation of the differentiated thyroid carcinoma available * WHO performance score 0-2 * metastatic sites lung and/or bone and/or nodal (radiologically measurable disease \> 1 cm) * life expectancy \> 6 months * patient has undergone total/near total thyroidectomy * no past history of sensitivity/reaction to 1311 Exclusion Criteria: * non iodine concentrating tumours * received chemotherapy or radiotherapy in 6 weeks * pregnant or breast feeding patients * iodine contrast injection in last 3 months
References
Publications (0)
Data not yet available
No reference posted for this study.